Unia Europejska - fiński - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiset aineet - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Finlandia - fiński - Fimea (Suomen lääkevirasto)

ayerst laboratories inc. wyeth ayerst laboratories - ecothiopati iodidum - jauhe silmätippoja varten - 0.6 mg/ml - ekotiopaatti

Finlandia - fiński - Fimea (Suomen lääkevirasto)

ayerst laboratories inc. wyeth ayerst laboratories - ecothiopati iodidum - jauhe silmätippoja varten - 1.25 mg/ml - ekotiopaatti

Finlandia - fiński - Fimea (Suomen lääkevirasto)

ayerst laboratories inc. wyeth ayerst laboratories - ecothiopati iodidum - jauhe silmätippoja varten - 2.5 mg/ml - ekotiopaatti

Finlandia - fiński - Fimea (Suomen lääkevirasto)

wyeth-ayerst lederle inc american cyanamid company - methotrexatum natricum - injektiokuiva-aine - metotreksaatti

Finlandia - fiński - Fimea (Suomen lääkevirasto)

wyeth-ayerst lederle inc american cyanamid company - kalsium folinas - injektioneste - 3 mg/ml - kalsiumfolinaatti

Finlandia - fiński - Fimea (Suomen lääkevirasto)

wyeth-ayerst lederle inc american cyanamid company - methotrexatum - injektioneste - 2.5 mg/ml - metotreksaatti

Finlandia - fiński - Fimea (Suomen lääkevirasto)

wyeth-ayerst lederle inc american cyanamid company - vancomycini hydrochloridum - infuusiokuiva-aine - 500 mg - vankomysiini

Unia Europejska - fiński - EMA (European Medicines Agency)

gedeon richter plc. - follitropiini alfa - anovulation - sukupuolihormonit ja genitaalijärjestelmään vaikuttavat aineet, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. kliinisissä tutkimuksissa näiden potilaiden käytettiin endogeenista seerumin lh-tasoa < 1. 2 iu / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Unia Europejska - fiński - EMA (European Medicines Agency)

n.v. organon - corifollitropiini alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - sukupuolihormonit ja genitaalijärjestelmään vaikuttavat aineet, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).